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ABSTRACT
Purpose: We aimed to assess the etiological role of apoptotic genes Bcl-2 and Bax in the background of
major obstetric and gynaecological diseases. Methods: Placental tissue samples were collected from 101
pregnancies with intrauterine growth restriction and 104 pregnancies with premature birth with 140
controll samples from term, eutrophic newborns. In addition, gene expression assessment of the genes Bax
and Bcl-2 was performed in 101 uterine leiomyoma tissue samples at our disposal with 110 control cases.
Gene expression levels were assessed by PCR method. Results: The expression of the Bcl-2 gene was
decreased in placental samples with intrauterine growth restriction. Significant overexpression of the
proapoptotic Bax gene was detected in samples from premature infants. Antiapoptotic Bcl-2 gene
expression was found to be significantly increased in fibroid tissues. Conclusion: Apoptosis plays a crucial
role in the development of the most common OB/GYN conditions. Decrease in the placental expression of
the antiapoptotic gene Bcl-2 may upset the balance of programmed cell death.
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INTRODUCTION
Programmed cell death (apoptosis) plays an important role during the development of the
placenta and in the regulation of its ageing during pregnancy [35]. The regulation of pro-
grammed cell death is complex; both proapoptotic (stimulating programmed cell death) and
antiapoptotic (inhibiting programmed cell death) genes are involved. Members of the Bcl-2 (B
cell lymphoma 2) protein family play a prominent role in this complex regulatory system [8, 21,
25, 39]. Based on structure and function, genes of the Bcl-2 family may also be classified as genes
with pro- and anti-apoptotic effect [4, 16, 37]. Genes with antiapoptotic effect include Bcl-2, Bcl-
xL (Bcl-extra long), A1, Bcl-w and Boo, whereas the proapoptotic group includes Bax, Bak, and
Box genes. Bcl-2 from the antiapoptotic group, and Bax from the proapoptotic group exert the
strongest biological effect; accordingly, we simply traced back the regulation and balance of the
apoptotic process in the investigated conditions to the establishment of the balance between
these two genes, and to the change in their activity [9, 38]. Several studies have confirmed that
the role of apoptosis increases during pregnancy with increasing gestational age, and that this is
related to the change in activity of the members of the Bcl-2 gene family [19, 43, 45]. Devel-
opment and ageing of the placenta are both essential for normal gestation and near-term
delivery. Several gestational pathological states have been related to the modified apoptotic
activity of trophoblast cells, such as intrauterine growth restriction, premature birth or
preeclampsia [1, 11, 14, 22, 23].
Changes in apoptotic activity play a role in the development of both benign and malignant
tumours. Uterine leiomyomas (benign tumours of the womb originating from smooth muscle)
are the most frequent benign tumours in women. Tumour growth is determined by increased
cell proliferation and/or decreased intensity of apoptosis. Based on previous data in the litera-
ture, it has been suggested that Bcl-2 and Bax gene expression is altered in fibroids compared to
normal myometrium [12, 27, 30, 47], although this has not yet been confirmed on a larger
patient population.
Intrauterine growth restriction (IUGR) is present when foetal weight falls below the 10th
percentile of the standard for sex and gestational age [17, 20, 41, 46]. IUGR may result from
placental dysfunction, foetal malformations (e.g. chromosomal abnormalities), intrauterine
infection (e.g. cytomegalovirus infection, toxoplasmosis), maternal diseases (e.g. kidney diseases,
autoimmune diseases) or environmental factors.
Premature birth is present when the pregnancy is terminated by birth before the 37th
gestational week. When gestational age cannot be determined accurately, premature birth is
defined if the infant’s birth weight stays below 2,500 g [13, 31, 42, 44].
Uterine fibroid is a benign tumour originating from the smooth muscle cells of the
womb, which develops mostly in women of child-bearing age, and its incidence increases with
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age [6, 26, 28, 34]. The most common symptoms caused by uterine fibroid are irregular bleeding
and pelvic pain. It may also lead to obstetric complications like infertility, recurrent abortions
and premature delivery, as well as to the compression of other pelvic organs. Although no gene
responsible for the development of uterine fibroids not being part of a syndrome has yet been
identified, familial accumulation reported in several studies indicates genetic determination of
the condition [18].
The aim of our study was to compare Bax (proapoptotic) and Bcl-2 (antiapoptotic) gene
expression patterns of placental samples from pregnancies with intrauterine growth restriction
or premature birth with those from healthy, eutrophic and mature pregnancies. It was also our
aim to assess the expression patterns of the most relevant Bax and Bcl-2 genes depending on the
severity of intrauterine growth restriction, and review clinical data that may significantly
contribute to the interpretation of gene expression results as well as possible interactions of
suspected etiological factors in the background of premature birth. Additionally, our aim was to
assess Bcl-2 and Bax gene activity in uterine fibroid tissue in a large number of cases and to
analyse it in view of clinical and demographical data.
MATERIALS AND METHODS
Patients (IUGR)
During our 1-year study, gene expression results of 101 placenta samples obtained during the
birth of infants with intrauterine growth restriction treated at the Semmelweis University 2nd
Department of Obstetrics and Gynaecology were compared to the gene expression levels of
placental samples obtained during the birth of 140 eutrophic newborns. In addition, basic
clinical and demographical data were also analysed. According to one of the study aspects,
pregnancies with growth restriction were classified into two groups by severity, depending on
the birth weight ranging between 0–5th and 5–10th percentile. After excluding intrauterine
infections, chromosome disorders, other foetal developmental disorders, maternal malnutrition,
multiple pregnancies and placental disorders, functional placental disorder was suggested as the
cause of intrauterine growth restriction.
Patients (premature birth)
During the one-year study, gene expression was investigated in 104 placental samples obtained
from pregnancies with premature birth. The diagnostic criteria for premature birth were
gestational age younger than 37th gestational week and/or birth weight below 2,500 g. Cases of
intrauterine growth restriction, multiple pregnancy, developmental disorders, maternal
anatomical disorder or induced premature birth were excluded from the study. In the investi-
gated cases, premature birth commenced by premature uterine activity and/or premature
rupture of the membranes.
Placental sampling, clinical and demographic data collection
In each case, a tissue sample, approximately 2 3 2 3 2 cm (8 cc) in size, was obtained from the
placenta at a distance of approximately 3 cm from the origin of the umbilical cord. Samples were
stored at 70 8C until further gene expression assessment. Assessed clinical data: maternal age,
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paternal age, obstetrics history, genetic history, other diseases, mother's birth weight, gestational
age at birth, foetal sex, weight gain during pregnancy, change of body mass index (BMI) during
pregnancy, carbohydrate metabolism disorder during pregnancy, other obstetrical disease
during pregnancy, infant's weight, Apgar score, smoking, and group B Streptococcus screening.
Regarding the way of delivery no distinction was made either in placental sampling or in gene
expression analysis.
Analyses were performed with the knowledge and consent of expectant mothers in all cases,
which was confirmed by their signature (Ethical approval number: TUKEB 114/2009).
Patients (uterine leiomyomas)
During the one-year study, gene expression results of tissue samples obtained from 101 women
undergoing surgery for uterine fibroid at the Semmelweis University 1st Department of
Obstetrics and Gynaecology were compared to the gene expression values of tissue samples
obtained from 110 women undergoing hysterectomy for causes other than uterine fibroid. The
preoperative diagnosis of uterine leiomyoma was established by gynaecological examination and
sonography in all cases. The type of surgery was determined according to clinical aspects, patient
age, possible further family planning and location, size and number of fibroid(s). The results of
gene expression assessment were not sorted according to the type of surgery (transvaginal
hysterectomy, transabdominal hysterectomy, fibroid enucleation). During the interpretation of
gene expression results only the cases where the diagnosis of uterine fibroid was also confirmed
by postoperative histological evaluation were included. Only those cases were assigned as
controls where the indication for hysterectomy was other than uterine fibroid or malignant
tumour. The fulfilment of these criteria was confirmed by histological evaluation in all cases.
Leiomyoma tissue sampling and clinical and demographic data collection
In the cases of myoma enucleation, tissue samples 1 3 1 3 1 cm (1 cc) in size were obtained
from the removed tumour when possible. Samples were stored at 70 8C until further gene
expression assessment. When multiple fibroids were removed, samples were obtained from each
of the resected tumours. In these cases, the average of the gene expression values of the indi-
vidual fibroids was calculated and considered as one value. For hysterectomy, the tissue sample
was obtained from the fibroid when possible; or if not, sampling was performed in the region
of the fundus of the removed womb at a volume of 6–8 cc. For control cases, a tissue sample
2 3 2 3 2 cm in size was removed from the region of the fundus of the uterus.
Assessed clinical data: age, family history of uterine fibroids, time of the first period, number
of pregnancies, number and way of deliveries, (total) length of lactation period(s) after preg-
nancy (pregnancies), unsuccessful pregnancies (spontaneous abortion, missed abortion, artificial
abortion), oral contraception, preoperative sonographic result, number, size and location of
uterine fibroids, type of the surgery, and the results of histological evaluation. For pregnancies,
the total amount of time spent being pregnant was used, given in weeks. An average of 37
gestational weeks per pregnancy was used for our analysis. (The time of pregnancies ending in
termination by spontaneous or artificial abortion, in view of their shortness, was not taken into
consideration).
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Gene expression assessment (IUGR, premature birth and uterine fibroid)
The total amount of RNA present in the placental and fibroid samples was extracted with the
Quick RNA Micropep Kit (Zymo Research), then RNA concentration was measured by the
NanoDrop spectrophotometer (NanoDrop). Reverse transcription (RT) was performed in a final
volume of 20 mL: using 5 mg of total RNA, 75 pmol of random hexamer primer, 10 mM of dNTP
(Invitrogen), 20 U M-MuLV Reverse Transciptase enzyme (MBI Fermentas) and 13 buffer
(MBI Fermentas). The reaction mixture was incubated at 42 8C for 2 h, then the enzyme was
inactivated at 70 8C for 15 min.
The reverse transcription reaction mixture was diluted threefold with nuclease-free water.
For real-time PCR, 1 mL of diluted cDNA (the equivalent of ∼15 ng RNA) and 1 3 SYBR Green
Master Mix (Applied Biosystems) were used. Primers were designed using the Primer Express
Software (Applied Biosystems) (primer sequences are presented in Table 1). Real-time PCR
reaction was performed with 1 mL cDNA, 1 pmol, gene-specific Forward and Reverse primers
and 1 3 SYBR Green PCR Master mix in a final volume of 20 mL. All real-time PCR reactions
were carried out with MX3000 Real-time PCR (Stratagen) equipment according to the following
protocol: 40 cycles, denaturation at 95 8C for 15 s, primer-annealing, chain lengthening and
detecting at 60 8C for 60 s. The relative expression of each gene was normalised for the human
b-actin gene.
Statistical analysis
The Stratagen MX3000 real time PCR software (Stratagen) was used to calculate gene
expression values. Threshold cycle value (Ct) is defined as the reaction time (real-time PCR
cycle time) by which the evaluating software detects a fluorescent signal that unequivocally
deviates from the baseline signal. The delta Ct value (ΔCt) demonstrates the difference be-
tween the Ct value of the target gene measured in the assessed sample and that of the internal
control gene (ΔCt5 Ctassessed gene  Ctinternal control gene). The a-value characterises the relative
difference of target genes between two different samples (ΔCtsample 1  ΔCtsample 2). The
natural logarithm of the 2ά value shows how the relative amount of the target gene RNA
compares between two samples. The UCL (upper confidence limit) and the LCL (lower
confidence limit) refer to the highest and lowest relative differences between assessed samples,
respectively.
A two-sample t-test was used to assess gene expression results (confidence interval 95%). The
degree of freedom was determined by Welch–Satterthwaite approximation. Gene expression
Table 1. Primers and sequences used for real-time PCR reactions in the gene expression assessments for
IUGR, premature birth and leiomyoma uterine
Name and ID of gene Forward primer Reverse primer
Bcl-2 (NM_000633) 59-ATGTGTGTGGAGAGCGTCAACC-39 59-TGAGCAGAGTCTTC
AGAGACAGCC-39
Bax (NM_004324) 59-CCTTTTCTACTTTGCCAGCAAAC-39 59-GAGGCCGTCCCA
ACCAC-39
b-Actin (M10277) 59-GGCACCCAGCACAATGAAG-39 59-GCCGATCCACACG
GAGTACT-39
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values were classified into the following groups: (1) overactive gene: if the Ln value of the
calculated data >1, P < 0.05; (2) underactivity: if the Ln value of the calculated data <1, P < 0.05;
(3) unchanged activity: if the Ln value of the calculated data <1, >1, P < 0.05. GraphPad Prism
3.0 (GraphPad Software Inc, La Jolla, CA, USA) software was used for all statistical evaluations.
To analyse demographic and clinical data, we created models with mathematical statistical
tools, using the SPSS software package. As multidimensional process we applied logistic
regression (due to the dichotomous dependent variables), analysis of variance (ANOVA) and
linear regression. Correlations were considered significant when P < 0.05.
RESULTS
Clinical data (IUGR)
Male:female ratio was 0.58 (64 boys; 37 girls) and 1.09 (boys: 73; girls: 67) in the intrauterine
growth restriction group and in the eutrophic control group, respectively (P < 0.05). The median
age of expectant mothers did not differ significantly (30.82 ± 4.34 years/IUGR/vs 31.45 ± 3.12
years/eutrophic/; P > 0.05), whereas significant differences were observed regarding weight gain
during pregnancy (14.8 kg/eutrophic/vs 10.9 kg/IUGR/) and change in body mass index (þ5.3/
eutrophic/vs 4.1/IUGR/) of pregnant women (P < 0.05).
Regarding the birth weight of expectant mothers, our data confirmed that the birth weight
(median: 2,830 g) of women delivering infants with birth weight between 0–5th percentile was
significantly lower than those delivering infants with birth weight between 5 and 10th percentile
(median: 3,120 g) (P < 0.05).
Clinical data (premature birth)
Boy:girl ratio was 0.89 (49 boys; 55 girls) and 1.09 (73 boys; 67 girls) among premature infants
and in the control group, respectively (P > 0.05). Median age of women giving birth prematurely
did not show any significant difference compared to the control group (30.7 ± 5.20 years/
premature birth/vs 31.4 ± 3.12 years/mature birth/) (P > 0.05).
Prenatal weight gains of pregnant women delivering mature and premature infants, that
were compared during the study, showed a significant difference in accordance with the shorter
gestational period preceding premature births (11.6 ± 4.6 kg/premature birth/vs 14.7 ± 2.6 kg/
mature birth/) (P < 0.05).
The rate of regular smokers with pregnancies terminating in premature birth was 26.9% (28/
104) compared to 7.1% in the mature control group (10/140) (P < 0.05).
Premature birth commenced with premature rupture of the membranes in 70.2% of cases
(73/104) and spontaneous uterine activity in 29.8% of cases (31/104).
Clinical data (uterine leiomyoma)
Patients treated for uterine leiomyoma were significantly younger (median age) than patients in
the control group (47.5 ± 12.1 years vs 54.7 ± 10.2 years; P < 0.05).
Regarding the median length of total time spent pregnant in weeks, our data showed that
women with leiomyomas spent a significantly shorter time in pregnancy (105.1 ± 8.2 weeks)
than patients in the control group (127.2 ± 9.1 week) (P < 0.05).
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Nulliparity was significantly more frequent among women with fibroids (32/101; 31.7%)
than in the control group (6/110; 5.5%) (P < 0.05).
Lactation period following pregnancy was, understandably, significantly shorter than in the
control group (2.4 ± 1.2 months vs 5.1 ± 2.2 months; P < 0.05).
The prevalence of the two most common symptoms of uterine leiomyomas (bleeding dis-
order, lower abdominal pain) together, as well as that of the bleeding disorder on its own was
significantly higher (P < 0.05) in the group of patients with uterine fibroids than among control
cases (Table 2).
Of the 101 leiomyoma cases, 40 enucleations (39.6%) and 61 hysterectomies (60.4%) were
performed.
Gene expression assessment
The expression of the proapoptotic Bax gene did not show any significant differences in the
samples from pregnancies with IUGR, whereas the antiapoptotic Bcl-2 gene showed a significant
Table 2. The incidence of the most common symptoms of leiomyoma uterine in the myoma and control
group
Myoma cases Control cases
n % n %
Symptoms Abdominal pain: negative; bleeding
disorder: negative
26 25.7 56 51.1
Abdominal pain: negative; bleeding
disorder: positive
28 27.0 21 19.2
Abdominal pain: positive; bleeding
disorder: negative
12 12.2 16 14.4
Abdominal pain: positive; bleeding
disorder: positive
35 35.1 17 15.3
Total 101 100 110 100
Table 3. Bax- and Bcl-2 gene expression activities in the placenta samples with intrauterine growth














Bax 3.18 ± 0.82 4.04 ± 0.67 0.86 ± 0.5 0.59 0.43 1.21 0.06 Not changed in
function
Bcl-2 3.18 ± 0.82 6.32 ± 0.86 3.14 ± 0.81 2.17 0.85 3.79 0.04 Underactivity
UCL: upper confidence limit.
LCL: lower confidence limit.
Significant difference: P < 0.05.
(I.) ΔCteutrophic 5 Ctassesed gene  Ctb-actin nIUGR 5 101.
(II.) ΔCtIUGR 5 Ctassesed gene  Ctb-actin neutrophic 5 140.
(III.) a 5 ΔCteutrophic  ΔCtIUGR.
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underactivity in the placenta samples with IUGR compared to control samples from eutrophic
pregnancies (P < 0.05) (Table 3).
No significant differences could be shown in Bax and Bcl-2 gene expression of placental
samples from foetuses with severe IUGR classified into the 0–5th percentile weight range,
compared to similar parameters of foetuses with milder intrauterine growth restriction of 5–10th
percentile (Table 4).
Regarding gene expression activity of placenta samples from premature infants, a significant
overexpression of the proapoptotic Bax gene could be detected compared to gene expression
activity in the mature control group (P < 0.05), whereas the antiapoptotic Bcl-2 gene did not
show any significant change in activity (Table 5).
Depending on gestational age, placental Bax and Bcl-2 gene expression values compared to
the placental values from term births were detected as follows: no significant difference was
present in the activity of antiapoptotic Bcl-2 gene in premature births at weeks 24–28, 28–32 and
Table 4. Bax and Bcl-2 gene expression of placental samples from foetuses with severe intrauterine growth
restriction classified into the 0–5th percentile weight range, compared to similar parameters of foetuses
with milder intrauterine growth restriction of 5–10th percentile
Name of




Bax 4.32 ± 0.46 3.76 ± 0.3 0.56 ± 0.28 0.38 0.06 Not changed in function
Bcl-2 6.92 ± 0.58 5.7 ± 0.64 1.22 ± 0.53 0.84 0.07 Not changed in function
A: 5–10 percentile IUGR placental sample; ntotal 5 101 (nA 5 60, nB 5 41).
B: 0–5 percentile IUGR placental sample.
ΔCtA 5 Ctassesed gene  Ctb-actin;
ΔCtB 5 Ctassesed gene  Ctb-actin;
a 5 ΔCtA  ΔCtB;
Significant difference: P < 0.05.
Table 5. Bax and Bcl-2 gene expression activities of placenta samples from premature infants compared to














Bcl-2 2.76 ± 0.48 2.53 ± 0.7 0.23 ± 0.6 0.15 1.12 0.91 0.07 Not changed
in function
Bax 2.97 ± 0.8 1.02 ± 0.65 1.95 ± 0.72 1.35 0.82 2.13 0.04 Overactivity
UCL: upper confidence limit.
LCL: lower confidence limit.
Significant difference: P < 0.05.
(I.) ΔCteutrophic 5 Ctassesed gene  Ctb-actin; npremature 5 104; neutrophic 5 140.
(II.) ΔCtpremature 5 Ctassesed gene  Ctb-actin;
(III.) a 5 ΔCteutrophic  ΔCtpremature.
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32–36, whereas the proapoptotic Bax gene demonstrated significant overexpression in prema-
ture births at weeks 28–32 and 32–36, and no change of activity in premature births at weeks
24–28, compared to similar values of control samples (Table 6).
The expression of the antiapoptotic Bcl-2 gene in uterine fibroid tissue samples was shown to
be significantly increased (P < 0.05) compared to expression values of samples in the control
group, whereas the expression of the proapoptotic Bax gene did not show any significant dif-
ference (Table 7).
When comparing Bcl-2 and Bax gene expression in cases with negative and positive family
histories of uterine fibroids, significant difference in gene expression activity was not identified.
Significant Bax gene expression difference was not detected according to the number of
fibroids compared to physiological myometrium; however, Bcl-2 gene activity showed a sig-
nificant correlation with the number of tumours (P < 0.05), i.e. overexpression was found to be
more pronounced in cases of multiple fibroids (Table 8).
When assessing Bcl-2 and Bax gene expression activity in relation to the length of lactation
period following pregnancies prior to the development of uterine fibroids, no significant
changes were detected compared to the gene activity in women who had not lactated previ-
ously, whereas Bcl-2 gene activity was shown to be higher in the case of a shorter lactation
period.
Table 6. Bax and Bcl-2 gene expression activities of placenta samples from premature infants compared to
gene expression activity in the mature control group based on gestational age
n Gestational age Bax Ln 2a P Bcl-2 Ln 2a P
15 Week 24–28. 0.87 0.03 0.03 0.05
25 Week 28–32. 1.56 0.06 0.58 0.06
64 Week 32–36. 1.41 0.04 0.4 0.06
npremature 5 104.
Significant difference: P < 0.05.















Bcl-2 8.24 ± 0.83 6.03 ± 0.82 2.21 ± 0.75 1.53 0.2 3.24 0.04 Overactivity
Bax 12.72 ± 1.01 13.93 ± 0.9 1.21 ± 0.95 0.83 1.24 1.77 0.06 Not changed
in function
UCL: upper confidence limit.
LCL: lower confidence limit.
Significant difference: P < 0.05.
(I.) ΔCtlnormal 5 Ctassesed gene  Ct b-actine.
(II.) ΔCtfibroid 5 Ctassesed gene  Ct b-actine.
(III.) a 5 ΔCtnormal  ΔCtfibroid.
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DISCUSSION
The clinical results obtained are rather referential and serve as adequate clinical characterisation of
the assessed patient population, as – based on the low number of cases – it has no statistical value.
Among environmental factors, the most important etiological factor of premature delivery
was shown to be smoking during pregnancy. Smoking decreases the amount of available oxygen
needed for intrauterine foetal development, and also decreases the level of serum IGF-1. The
latter may also play a role in the imbalance of energy intake – oxygenation axis which is essential
for the intrauterine health of the foetus [10].
Confirming ample literature data, our research also showed an inverse ratio between the
number of pregnancies and incidence of uterine fibroids [36].
Regarding lactation and incidence of uterine fibroids, our results have shown that women
treated for uterine fibroid had been pregnant fewer times and for shorter periods of time than
patients in the control group; therefore, the rate of non-lactating women in the group of uterine
fibroids was found to be significantly higher (27.4% vs 3%). Prolactin, the hormone regulating
the lactation period, stimulates rather than inhibits the development of fibroids [33].
Embedding of placental tissue into the uterine wall is an aggressive process from a histological
aspect, which brings the growth of malignant tumours into mind to some degree. Genes regulating
apoptosis can be identified during the entire gestational period [24]. Although some studies
reported an overexpression of the antiapoptotic Bcl-2 gene at the end of pregnancy [5], in the case of
eutrophic intrauterine foetal development, significantly more data are available confirming under-
activity [2, 32]. The expression of the proapoptotic Bax gene during physiological pregnancy probably
increases near to the end of pregnancy, or at least that is being suggested by literature data [19, 45].
Based on assessments on placenta samples from pregnancies with intrauterine growth re-
striction, Barrio and his group confirmed decreased expression of the antiapoptotic Bcl-2 gene,
whereas Agata and colleagues attributed the apoptotic imbalance to the overexpression of the
proapoptotic Bax gene, and found placental Bcl-2 gene expression to be unchanged [2, 25]. Our
study data match the results of Barrio et al., i.e. we could confirm for a large number of cases that
in case of intrauterine growth restriction, a decrease in placental Bcl-2 gene activity can be
observed [29] resulting in a less dominating presence of apoptosis-inhibiting mechanisms [2]. In
pregnancies with intrauterine growth restriction, Agata et al. found an increase in placental Bax
gene expression activity which stimulates the process of programmed cell death [25], and this
Table 8. The Bcl-2 and Bax gene expression activity in relation to the number of fibroids compared to
physiological myometrium
Number of fibroids a value ± SE(a) Ln 2a P
Gene expression
changes
Bcl-21 (n 5 53) 2.01 ± 0.69 1.13 0.04 Overactivity
Bcl-22 (n 5 13) 1.89 ± 0.8 1.37 0.04 Overactivity
Bcl-2more than 2 (n 5 23) 2.3 ± 0.74 1.69 0.04 Overactivity
Bax1 (n 5 53) 0.65 ± 0.98 0.45 0.06 Not changed in function
Bax2 (n 5 13) 0.02 ± 0.8 0.01 0.05 Not changed in function
Baxmore than 2 (n 5 23) 0.42 ± 0.64 0.29 0.05 Not changed in function
a 5 ΔCtnormal  ΔCtfibroid.
Control gene: b-aktin.
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was also confirmed by Heazell et al.'s studies [21]. Unlike these previous results, our analysis did
not show any difference in placental Bax gene activity in cases of intrauterine growth restriction
compared to the control group.
De Falco et al. recommends the simultaneous assessment of Bcl-2 and Bax gene expression
activities during physiological pregnancies for a flexible interpretation of the phenomenon of
apoptosis [9]. This model allows simultaneous review of the changes in the activity of the most
important proapoptotic and antiapoptotic genes, also highlighting the fact that one cannot inter-
preted without the other. Due to the placental functional disorders present in pathological preg-
nancies (such as IUGR) this model is even more useful, as there is a higher chance that pathological
conditions are associated with changes in the regulation of programmed cell death. Based on the
above model, our study results match the hypothesis suggesting changes in the activity of genes that
exert stimulating and inhibitory effect on the process of apoptosis in the case of IUGR. However,
gene expression observed in our study confirmed a decrease in antiapoptotic effects in the back-
ground of IUGR rather than an increase in gene activity stimulating programmed cell death.
The expression pattern of the assessed genes (Bcl-2, Bax) that influence programmed cell
death did not show any difference in relation to the degree of underdevelopment of the foetus
with intrauterine growth restriction [3].
Several studies investigated the role of apoptosis in the development of the premature rupture
of the membranes, which is the most common cause for premature birth [40]. Fortunato et al.
detected a definitive increase in Bax and a decrease in Bcl-2 gene activity in placental samples from
premature births [15]. We also observed an undeniable increase in the activity of the proapoptotic
Bax gene in placenta samples from premature births; however, we did not detect any changes in
gene expression regarding the antiapoptotic Bcl-2 gene; i.e. in the process of apoptosis contributing
to the initiation of premature birth, the overexpression of the activating Bax gene might play the
primary role, and the underactivity of the inhibitory Bcl-2 gene is less important.
Gestational age at the time of premature birth is a relevant aspect regarding the placental
activity of the proapoptotic Bax gene, as it shows an increase in activity in premature births after
the 28th gestational week, whereas no change at all was identified in the activity of the Bcl-2
gene. Apoptosis might play a less important part in premature births between gestational weeks
24–28 than in cases following the 28th gestational week.
In both benign and malignant tumour growth, an imbalance between cell division and death can
always be observed. According to our results, the Bcl-2 gene is overexpressed in uterine leiomyomas
compared to the gene expression pattern in the normal myometrium, indicating that the imbalance
of apoptosis playing a role in the development of fibroids may be attributed to the overactivity of an
antiapoptotic gene (Bcl-2), while the proapoptotic Bax gene is functioning normally [7].
The gene expression analysis of apoptosis in case of the most common OB/GYN diseases
may contribute to successful research for the efficient prediction of IUGR, premature birth as
well as uterine fibroids in the future.
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